Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 24-month, Multi-center, Open-label, Randomized, Controlled Trial to Investigate Efficacy, Safety and Evolution of Cardiovascular Parameters in de Novo Renal Transplant Recipients After Early Calcineurin Inhibitor to Everolimus Conversion.

Next Previous
Search
Trial Profile

A 24-month, Multi-center, Open-label, Randomized, Controlled Trial to Investigate Efficacy, Safety and Evolution of Cardiovascular Parameters in de Novo Renal Transplant Recipients After Early Calcineurin Inhibitor to Everolimus Conversion.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 08 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Everolimus (Primary) ; Ciclosporin; Tacrolimus
  • Indications Renal transplant rejection
  • Focus Registrational; Therapeutic Use
  • Acronyms ELEVATE
  • Sponsors Novare Pharmaceuticals; Novartis

Most Recent Events

  • 03 May 2017 Results of a subanalysis from the ELEVATE study comparing the renal function outcomes by the presence of preformed and de novo donor-specific antibody in kidney transplant recipients receiving everolimus vs standard calcineurin inhibitor, presented at the 2017 American Transplant Congress.
  • 03 May 2017 Results of subanalysis from ELEVATE trial assessing effect of Human leukocyte antigen (HLA)-DQ mismatch on efficacy outcome and renal function presented at the 2017 American Transplant Congress
  • 03 May 2017 Results of post hoc analysis assessing effect of everolimus regimen on graft outcomes presented at the 2017 American Transplant Congress

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top